
EFPIA appoints comms head from Lilly
pharmafile | February 18, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | EFPIA, English, liam, lilly
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has hired its new comms director from Eli Lilly.
Liam English who is currently Lilly’s communications director will take up his post on the 12 May. He has previously held senior comms roles in the BBC and the European Commission.
In his new role English will lead a small team with responsibility for developing comms plans and reputation initiatives, in partnership with the EFPIA’s management and members.
English has over 15 years’ experience in the communications field with a variety of organisations that also include the UK’s HM Treasury, Department of Health and Cabinet Office.
In 2011 he took on the role of associate communications director for the Australia, Canada and Europe region at Lilly. This included establishing LillyPadEU, the first social media blog from a pharma firm to focus purely on EU policy matters.
Richard Bergström, EFPIA director general, said: “I am delighted to welcome Liam to EFPIA, who joins at a critical time of change and evolution for the industry in Europe.”
English added: “This is such an exciting time to be joining the team at EFPIA. The pharmaceutical industry is built on a common core purpose to make life better for individuals and communities, but this fact is sometimes overlooked or tangled in the complexities of political and policy debates.”
Related Content
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …






